Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy

Seyfried, Nicole; Mahran, Amr; Obmann, Verena Carola; Jiang, Yun; Wright, Katherine Landau; Nakamoto, Dean A.; Patel, Indravadan; Conroy, Britt; Ponsky, Lee; Gulani, Vikas

doi:10.2214/ajr.20.24918

Cited by 7 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 lists the characteristics of the studies selected [ 8 – 18 ]. The total number of patients enrolled was 488.…”

Section: Resultsmentioning

confidence: 99%

“…Four of the 11 studies (36%) were prospective. In all cases, at least 2 PET/CT or PET/MRI scans had been obtained, one before and one after therapy [ 8 – 14 , 16 – 18 ]. Zimmerman et al [ 15 ] reported on 3 PET/CT scans obtained before, during and after CRT.…”

Section: Resultsmentioning

confidence: 99%

“…Zimmerman et al [ 15 ] reported on 3 PET/CT scans obtained before, during and after CRT. In 6 studies, a combined therapy was used to treat borderline or resectable PDAC [ 8 , 11 , 12 , 14 – 16 , 18 ]. PET/MRI was only used in one study [ 18 ].…”

Section: Resultsmentioning

confidence: 99%

“…Table 2 shows methodological details for the studies considered. The most often used parameters of response to therapy were the reduction in the maximum standardized uptake value (SUV) or the peak standardized uptake lean mass (SUL) [ 8 – 16 , 18 ]. In particular, reductions in SUV max [or the regression index (RI)] of more than 50% were associated with a more favorable response to therapy than in the case of smaller reductions [ 8 , 10 , 11 , 14 , 15 , 18 ].…”

Section: Resultsmentioning

confidence: 99%

“…The most often used parameters of response to therapy were the reduction in the maximum standardized uptake value (SUV) or the peak standardized uptake lean mass (SUL) [ 8 – 16 , 18 ]. In particular, reductions in SUV max [or the regression index (RI)] of more than 50% were associated with a more favorable response to therapy than in the case of smaller reductions [ 8 , 10 , 11 , 14 , 15 , 18 ]. In two studies, changes in metabolic volume parameters or other specific criteria (i.e., PET response criteria in solid tumors—PERCIST or SUV max × blood glucose level/100−SUV gluc ) were also used to assess response to neoadjuvant therapy [ 13 , 16 ], demonstrating the additional value of alternative PET metrics in predicting and assessing response to therapy.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review

et al. 2021

View full text Add to dashboard Cite

The aim of the present systematic review is to examine the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) associated with computed tomography (CT) or magnetic resonance imaging (MRI) in assessing response to preoperative chemotherapy or chemoradiotherapy (CRT) for patients with borderline and resectable pancreatic ductal adenocarcinoma (PDAC). Three researchers ran a database query in PubMed, Web of Science and EMBASE. The total number of patients considered was 488. The most often used parameters of response to therapy were the reductions in the maximum standardized uptake value (SUVmax) or the peak standardized uptake lean mass (SULpeak). Patients whose SUVs were higher at the baseline (before CRT) were associated with a better response to therapy and a better overall survival. SUVs remaining high after neoadjuvant therapy correlated with a poor prognosis. Available data indicate that FDG PET/CT or PET/MRI can be useful for predicting and assessing response to CRT in patients with resectable or borderline PDAC.

show abstract

“…Table 1 lists the characteristics of the studies selected [ 8 – 18 ]. The total number of patients enrolled was 488.…”

Section: Resultsmentioning

confidence: 99%